# Ketamine Clinic Marketing Compliance: Off-Label Psychiatric Advertising, FDA Warnings, and What Still Runs Ketamine infusion marketing combines off-label promotion, psychiatric disease-claim rules, controlled-substance considerations, and specific FDA guidance warning against unapproved ketamine therapy marketing. Here's the full compliance framework. By RegenCompliance Editorial (FDA/FTC compliance desk). Published 2026-02-27. Reading time 10 minutes. Canonical page: https://regencompliance.ai/blog/ketamine-clinic-marketing-compliance Ketamine clinics have grown rapidly since the mid-2010s, with marketing that frequently claims treatment of depression, anxiety, PTSD, chronic pain, and other serious psychiatric and neurological conditions. The FDA has specifically issued guidance warning against unapproved ketamine therapy marketing patterns. Ketamine is also a Schedule III controlled substance, adding DEA considerations on top of FDA and FTC issues. Ketamine clinic marketing operates in one of the most compliance-dense environments in current healthcare practice. ## The regulatory baseline Ketamine is an FDA-approved anesthetic - that’s its on-label indication. Esketamine (Spravato) is FDA-approved for treatment-resistant depression with specific protocols. Most ketamine clinic use is therefore off-label: intravenous ketamine for depression, anxiety, PTSD, chronic pain, and other indications. Off-label *use* is generally permissible clinical practice; off-label *marketing*carries FDA exposure. The FDA has issued specific guidance warning against unapproved marketing of ketamine, including [compounded forms](https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws). The FTC has pursued ketamine clinic marketing for substantiation issues around specific outcome claims under the [Health Products Compliance Guidance](https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance). State medical boards have taken action on ketamine clinic supervision and marketing issues in multiple jurisdictions. Controlled substance considerations Ketamine is a Schedule III controlled substance. Marketing considerations beyond FDA and FTC include DEA registration-based restrictions, telehealth Ryan Haight Act implications for prescribing, and state-specific controlled substance marketing rules. These considerations specifically require healthcare regulatory counsel familiar with both FDA and DEA frameworks. ## The specific problem patterns ### Pattern 1: Disease-treatment claims Non-compliant “Ketamine infusion therapy for depression, anxiety, PTSD, and chronic pain.” Compliant alternative “Our practice offers IV ketamine infusions for appropriate candidates with treatment-resistant conditions; specific indications and clinical appropriateness are determined at consultation.” Why: Listing specific psychiatric and neurological diseases as treated indications is off-label marketing of an FDA-approved anesthetic. The compliant alternative uses clinical-appropriateness framing. ### Pattern 2: Efficacy percentages and outcome claims Non-compliant “70% of patients see relief from depression within hours.” Compliant alternative “Published studies of IV ketamine in treatment-resistant depression have shown variable response rates depending on study design and patient population. Individual outcomes vary significantly and depend on many factors.” Why: Specific outcome percentages require substantiation meeting the FTC standard - which most practice-level substantiation files do not meet. Citing the underlying research with appropriate qualifications is compliant. ### Pattern 3: “FDA-approved ketamine therapy” Non-compliant “Our FDA-approved ketamine therapy for mental health.” Compliant alternative “Ketamine is FDA-approved as an anesthetic. Esketamine (Spravato) has specific FDA-approved psychiatric indications. Most IV ketamine psychiatric use is off-label clinical application.” Why: Ketamine's off-label psychiatric use is not FDA-approved for those indications. 'FDA-approved ketamine therapy' misrepresents the approval status for the marketed use. ### Pattern 4: Suicidality and crisis marketing Non-compliant “Ketamine rapidly reduces suicidal ideation - get help now.” Compliant alternative “(Remove suicidality-specific marketing claims. Crisis-targeted marketing of off-label psychiatric treatment raises heightened FDA and FTC concerns; crisis intervention is outside the scope of clinic marketing.)” Why: Marketing targeting patients in suicidal crisis raises both consumer-protection heightened-scrutiny issues and specific FDA concerns about off-label psychiatric marketing. This is a category where removal is safer than restructuring. ### Pattern 5: At-home ketamine marketing Non-compliant “At-home ketamine treatment - convenient, affordable, effective.” Compliant alternative “(This entire category faces heightened FDA and DEA scrutiny. Telehealth ketamine prescribing for home use has been specifically warned against by the FDA; marketing should involve healthcare counsel familiar with current Ryan Haight Act and FDA guidance.)” Why: At-home ketamine marketing is currently one of the highest-risk healthcare marketing categories. The FDA has issued specific warnings; the DEA has investigated specific operations. Aggressive marketing in this category is not advisable. ### Pattern 6: Celebrity/testimonial-driven marketing Ketamine clinic marketing frequently includes patient testimonials describing dramatic improvement from specific conditions. These testimonials carry the disease-treatment claim into your marketing regardless of how the clinic itself frames the service. They also frequently lack typical-experience and material-connection disclosures. See our [testimonial compliance guide](https://regencompliance.ai/blog/healthcare-testimonial-compliance) for a full framework. ## Compliant ketamine marketing framework ### Candidacy-forward rather than indication-forward Market the practice as offering IV ketamine for appropriate candidates with treatment-resistant conditions, with specific indications determined at consultation. Avoid listing specific psychiatric or pain conditions in public marketing copy. The clinical conversation happens at consultation. ### Clinical context framing “IV ketamine as part of a comprehensive treatment plan” positions the service as a clinical intervention rather than a standalone consumer purchase. This reflects both clinical best practice and regulatory expectation. ### Evidence honesty The evidence for IV ketamine in various psychiatric indications is genuinely developing - some stronger than others. Honest framing acknowledges this: “Clinical research on IV ketamine for treatment-resistant conditions continues. We offer this as an option for patients who have not responded to standard treatment approaches.” ### Integration with other care “We coordinate with your primary mental health provider and incorporate IV ketamine into your broader treatment plan” - this framing reflects the standard of care many responsible ketamine clinics follow and is compliance-safer than standalone-treatment framing. See also our [mental health practice marketing guide](https://regencompliance.ai/blog/mental-health-practice-marketing-compliance) for the broader psychiatric marketing framework. ### Esketamine (Spravato) separately If you offer esketamine (Spravato), its FDA-approved psychiatric indication allows more specific marketing of that product for its approved use. Clearly separate esketamine marketing (which can appropriately discuss its approved indication) from IV ketamine marketing (which is off-label). ## Platform-specific issues Ketamine marketing runs into additional platform-level restrictions: - **Meta.** Mental health treatment ads face specific policy layers. Aggressive ketamine marketing regularly runs into ad rejection. - **Google Ads.** Ketamine clinic advertising often requires LegitScript certification; see our [Google Ads healthcare guide](https://regencompliance.ai/blog/google-ads-healthcare-advertising-policy) for category-level restrictions. - **TikTok.** Mental health content has platform- level community guidelines in addition to advertising policy. ## Frequently asked questions ### Can I discuss ketamine for specific conditions in any marketing? Educational content that discusses the clinical research on ketamine in specific conditions, without tying that research to specific treatment claims about your practice, is generally lower-risk than direct promotional marketing of specific indications. The line between education and promotion matters and should involve counsel review. ### What about the ongoing Ryan Haight Act telehealth question? Telehealth prescribing of controlled substances including ketamine is in active regulatory flux. The DEA has issued multiple guidance updates. Telehealth ketamine operations must maintain current awareness of specific prescribing rules; marketing should not rely on prescribing patterns that may become restricted. ### Is ketamine infusion different from ketamine troches or lozenges? Yes, legally and regulatorily. IV ketamine is administered under direct medical supervision. Ketamine troches for at-home use raise separate controlled-substance and prescribing-scope issues. Marketing each form carries distinct considerations. ### Do I need a psychiatrist on staff? This is a clinical and state-licensure question, not a marketing question. Scope-of-practice and supervision rules for ketamine administration vary by state. Marketing that implies psychiatric specialization when the prescriber is not a psychiatrist is a separate misrepresentation issue. ### Are there ketamine clinic enforcement examples to study? The FDA has issued specific warnings about compounded ketamine marketing. Various state medical boards have taken action on ketamine clinic scope-of-practice and marketing issues. These are publicly available and can inform compliance review. ### What’s the most conservative defensible marketing approach? Practice-forward framing: describe the clinical team, the evaluation process, the treatment environment, and the integration with broader mental health care - without specific indication claims or outcome numbers in public marketing. Conversions happen at consultation, where the more-detailed clinical conversation appropriately occurs. Key Takeaways - Ketamine's FDA-approved indication is as an anesthetic; most ketamine clinic use is off-label and cannot be marketed with specific FDA-approved framing for psychiatric indications. - The FDA has specifically warned against unapproved ketamine marketing patterns - this is a current enforcement focus. - Controlled-substance status adds DEA and Ryan Haight Act considerations on top of FDA/FTC rules. - Candidacy-forward and evaluation-forward marketing is both clinically appropriate and compliance-safer than indication-forward marketing. - At-home ketamine marketing and crisis-targeted marketing are particularly high-risk and should involve counsel review before running. --- RegenCompliance is FDA/FTC compliance scanning software for healthcare marketing, operated by Regen Portal LLC. Educational compliance tool, not legal advice. Not affiliated with the FDA or FTC. Contact: support@regencompliance.ai. Full site index for AI agents: https://regencompliance.ai/llms.txt